2015
What is quality, and can we define it in lung cancer?—the case for quality improvement
Farjah F, Detterbeck FC. What is quality, and can we define it in lung cancer?—the case for quality improvement. Translational Lung Cancer Research 2015, 4: 365-72. PMID: 26380177, PMCID: PMC4549465, DOI: 10.3978/j.issn.2218-6751.2015.07.12.Peer-Reviewed Original Research
2003
Are Statins Indicated for the Primary Prevention of CAD in Octogenarians? Angagonist Viewpoint
Foody JM, Krumholz HM. Are Statins Indicated for the Primary Prevention of CAD in Octogenarians? Angagonist Viewpoint. The American Journal Of Geriatric Cardiology 2003, 12: 357-360. PMID: 14610384, DOI: 10.1111/j.1076-7460.2003.02912.x.Peer-Reviewed Original ResearchConceptsCoronary artery diseasePrimary preventionArtery diseaseOvert coronary artery diseaseRisk of myositisCardiovascular disease eventsRole of statinsUse of statinsAge 65 yearsBalance of risksCardiovascular eventsStatin therapyPatient preferencesCholesterol levelsCardiovascular diseaseOctogenariansClinical uncertaintyDisease eventsCurrent evidenceStatinsAge groupsDiseasePreventionRiskMyositis
2001
Preevaluation of Clinical Trial Data: The Case of Preemptive Cytomegalovirus Therapy in Patients with Human Immunodeficiency Virus
Paltiel A, Goldie S, Losina E, Weinstein M, Seage G, Kimmel A, Zhang H, Freedberg K. Preevaluation of Clinical Trial Data: The Case of Preemptive Cytomegalovirus Therapy in Patients with Human Immunodeficiency Virus. Clinical Infectious Diseases 2001, 32: 783-793. PMID: 11229847, DOI: 10.1086/319223.Peer-Reviewed Original ResearchMeSH KeywordsAIDS-Related Opportunistic InfectionsAntiviral AgentsChemopreventionCost-Benefit AnalysisCytomegalovirusCytomegalovirus InfectionsGanciclovirHIV InfectionsHumansModels, BiologicalPolymerase Chain ReactionPredictive Value of TestsQuality-Adjusted Life YearsSensitivity and SpecificityValganciclovirConceptsHuman immunodeficiency virusDuration of survivalPreemptive therapyCMV casesImmunodeficiency virusCMV polymerase chain reactionEnd-stage HIV diseaseUpcoming trialsCMV preemptive therapySalvage antiretroviral therapyCells/microLClinical trial dataCMV prophylaxisAntiretroviral therapyHIV diseaseComplication rateEfficacy assumptionsPolymerase chain reactionDisease progressionClinical uncertaintyDrug effectsPatientsTrial dataTherapyChain reaction
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply